Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL217304 | 0.84 | ACHE (0.37) | ACHE | |
| SCHEMBL814821 | 0.82 | ACHE (0.32) | ACHE | |
| SCHEMBL14658142 | 0.76 | — | — | |
| SCHEMBL29829773 | 0.76 | — | — | |
| SCHEMBL218611 | 0.76 | — | — | |
| SCHEMBL813892 | 0.75 | ACHE (0.31) | ACHE | |
| Benzene SCHEMBL28371694 | 0.74 | CA1 (0.31) | — | |
| SCHEMBL217782 | 0.74 | CA1 (0.33) | — | |
| SCHEMBL6066101 | 0.74 | TAAR1 (0.35) | ACHE | |
| SCHEMBL31008825 | 0.73 | APOBEC3A (0.47) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058372-B2 | Catalyst composition II | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2011-11-15 | — | — | US | claimed |
| US-20080319147-A1 | Catalyst Composition II | EXXONMOBIL CHEMICAL PATENTS INC. | 2008-12-25 | — | — | US | claimed |
| US-7371803-B2 | Catalyst composition II | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2008-05-13 | — | — | US | claimed |
| US-20070066776-A1 | Catalyst composition II | SOLAN GREGORY A | 2007-03-22 | — | — | US | claimed |
| US-7189791-B2 | Catalyst composition II | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-03-13 | — | — | US | claimed |
| EP-1641842-A2 | POLYMERIZATION AND OLIGOMERIZATION CATALYST WITH TRIDENTATE OR TETRADENTATE LIGAND | Exxonmobil Chemical Patents Inc. (US) | 2006-04-05 | — | — | EP | claimed |
| US-20040266961-A1 | Catalyst composition II | EXXONMOBIL CHEMICAL PATENTS INC. | 2004-12-30 | — | — | US | claimed |
| WO-2004106390-A2 | POLYMERIZATION AND OLIGOMERIZATION CATALYST WITH TRIDENTATE OR TETRADENTATE LIGAND | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2004-12-09 | — | — | WO | claimed |
| US-8058372-B2 | Catalyst composition II | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-7820582-B2 | Catalyst composition | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20080319147-A1 | Catalyst Composition II | EXXONMOBIL CHEMICAL PATENTS INC. | 2008-12-25 | — | — | US | disclosed |
| US-7371803-B2 | Catalyst composition II | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2008-05-13 | — | — | US | disclosed |
| US-20070191607-A1 | Catalyst composition | EXXONMOBIL CHEMICAL PATENTS INC. | 2007-08-16 | — | — | US | disclosed |
| EP-1603929-B1 | SOLUBLE GROUP-10 ALPHA-DIIMINE CATALYST PRECURSORS | EXXONMOBIL CHEM PATENTS INC (US) | 2007-08-01 | — | — | EP | disclosed |
| EP-1603956-A2 | CATALYST COMPOSITION | ExxonMobil Chemical Patents, Inc., A Corporation of the State of Delaware (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20040266961-A1 | Catalyst composition II | EXXONMOBIL CHEMICAL PATENTS INC. | 2004-12-30 | — | — | US | disclosed |
| WO-2004106390-A2 | POLYMERIZATION AND OLIGOMERIZATION CATALYST WITH TRIDENTATE OR TETRADENTATE LIGAND | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20040242893-A1 | Catalyst composition | EXXONMOBIL CHEMICAL PATENTS INC. | 2004-12-02 | — | — | US | disclosed |
| WO-2004085497-A2 | CATALYST COMPOSITION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2004-10-07 | — | — | WO | disclosed |
| WO-2004083224-A1 | SOLUBLE GROUP-10 α-DIIMINE CATALYST PRECURSORS, | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242893-A1 | Catalyst composition | MLX, BMX, CDYL | ACHE 3134/4885 |
| US-20040266961-A1 | Catalyst composition II | MLX, CBX2, BMX | ACHE 3557/4885 |
| US-20070191607-A1 | Catalyst composition | MLX, LMNB2, TPX2 | ACHE 2458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.